| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. [PubChem] |
| Indication |
Used in the management of diabetes mellitus type 2 (adult-onset). |
| Pharmacology |
Acetohexamide is an intermediate-acting, first-generation oral sulfonylurea. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. Acetohexamide has one-third the potency of chlorpropamide, and twice the potency of tolbutamide; however, similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas. |
| Toxicity |
Oral, rat LD50: 5 gm/kg; Oral, mouse LD50: >2500 mg/kg. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Extensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide. Hydroxyhexamide is believed to be responsible for prolonged hypoglycemic effects. |
| Absorption |
Rapidly absorbed from the GI tract. |
| Half Life |
Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours. |
| Protein Binding |
90% |
| External Links |
|